<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Imperial Clinical Research Services Blog</provider_name><provider_url>https://www.imperialcrs.com/blog</provider_url><author_name>Dan McDonald</author_name><author_url>https://www.imperialcrs.com/blog/author/dmcdonald/</author_url><title>Essential Tips for Enrolling Rare Disease Trials</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="Z2MxnCs2DM"&gt;&lt;a href="https://www.imperialcrs.com/blog/business-insights/rare-disease-enrollment/"&gt;Essential Tips for Enrolling in Rare Disease Clinical Trials&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.imperialcrs.com/blog/business-insights/rare-disease-enrollment/embed/#?secret=Z2MxnCs2DM" width="600" height="338" title="&#x201C;Essential Tips for Enrolling in Rare Disease Clinical Trials&#x201D; &#x2014; Imperial Clinical Research Services Blog" data-secret="Z2MxnCs2DM" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.imperialcrs.com/blog/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://www.imperialcrs.com/blog/wp-content/uploads/2020/07/AdobeStock_298945792.1200x800.jpg</thumbnail_url><thumbnail_width>1200</thumbnail_width><thumbnail_height>800</thumbnail_height><description>The last decade has seen an explosion in clinical trials for therapies focused on rare diseases. PhRMA reports that there are more than 800 orphan drugs currently in development or regulatory review.</description></oembed>
